Clene Inc. (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company specializing in neurodegenerative disease research, will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City.
President and CEO Rob Etherington will be available for one-on-one meetings with investors and analysts from 9 a.m. to 3 p.m. ET. The conference provides an opportunity for the company to discuss its ongoing research into neurological conditions, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis.
The company's primary investigational therapy, CNM-Au8®, targets mitochondrial function and the NAD pathway while reducing oxidative stress. This innovative approach aims to improve central nervous system cells' survival and function, potentially offering new treatment options for patients with challenging neurological disorders.
For investors and healthcare professionals, the conference represents a critical opportunity to gain insights into Clene's research progress and potential breakthrough treatments in neurodegenerative disease management.
